Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report)’s share price crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.28 and traded as high as $1.35. Akari Therapeutics shares last traded at $1.31, with a volume of 16,751 shares traded.
Wall Street Analyst Weigh In
Separately, Wall Street Zen started coverage on Akari Therapeutics in a research report on Wednesday, May 21st. They set a “sell” rating for the company.
Read Our Latest Stock Analysis on Akari Therapeutics
Akari Therapeutics Stock Performance
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
See Also
- Five stocks we like better than Akari Therapeutics
- Technology Stocks Explained: Here’s What to Know About Tech
- Is Meta Plotting a Stablecoin Comeback Years After Libra’s Flop?
- Best Stocks Under $5.00
- Silver’s Options Sizzle: Are Traders Betting on a Breakout?
- Why Invest in 5G? How to Invest in 5G Stocks
- AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio?
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
